Publication:
Unintentional monotherapy in rheumatoid arthritis patients receiving tofacitinib and drug survival rate of tofacitinib

Simple item page
dc.contributor.authorİNANÇ, GÜZİDE NEVSUN
dc.contributor.authorsİNANÇ G. N., Abacar K. Y., ÖZTÜRK M. A., TUFAN A., Karadeniz H., SARI İ., CAN G., Erez Y., PEHLİVAN Y., DALKILIÇ H. E., et al.
dc.date.accessioned2023-12-18T07:15:00Z
dc.date.available2023-12-18T07:15:00Z
dc.date.issued2023-12-01
dc.description.abstractObjective To determine the rate of unintentional monotherapy (UM; switching to monotherapy from combination therapy of patients\" own volition) in rheumatoid arthritis patients receiving tofacitinib and to evaluate tofacitinib survival rate. Methods This national, multicenter study included patients\" data from the TURKBIO Registry. Demographics, clinical characteristics, disease duration and activity, comorbidities, and treatments were analyzed. Results Data of 231 rheumatoid arthritis patients (84.8% female, median age, 56 years) were included; 153 were initially prescribed combination therapy and continued to their therapies; 31 were initially prescribed combination therapy but switched to monotherapy on their own volition (UM); 21 were initially prescribed monotherapy and switched to combination therapy; 26 were initially prescribed monotherapy and continued to their therapies. The rate of comorbidities at the time of data retrieval was higher in the UM group than in the combination group (83.3% vs. 60.3%, p = 0.031). Presence of comorbidities was a significant factor affecting switching to monotherapy (p = 0.039; odds ratio, 3.29; 95% confidence interval, 1.06-10.18). The combination and UM groups did not differ regarding remission rate assessed by Disease Activity Score 28-joint count C-reactive protein (60.5% and 70%, respectively; p = 0.328). Drug survival rates of the UM and combination groups did not differ. The median drug survival duration of tofacitinib was 27+ months with 1- and 4-year drug survival rates of 89.6% and 60.2%, respectively, in the UM group. Conclusions Although 13.4% of the study population started monotherapy unintentionally, drug survival and remission rates of the UM and combination groups were not different. Comorbidity was a factor affecting transition from combination therapy to monotherapy.
dc.identifier.citationİNANÇ G. N., Abacar K. Y., ÖZTÜRK M. A., TUFAN A., Karadeniz H., SARI İ., CAN G., Erez Y., PEHLİVAN Y., DALKILIÇ H. E., et al., "Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib", Journal of Clinical Rheumatology, cilt.29, sa.8, ss.365-369, 2023
dc.identifier.doi10.1097/rhu.0000000000002026
dc.identifier.endpage369
dc.identifier.issn1076-1608
dc.identifier.issue8
dc.identifier.startpage365
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85177503356&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/295685
dc.identifier.volume29
dc.language.isoeng
dc.relation.ispartofJournal of Clinical Rheumatology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectImmunology and Rheumatology
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectROMATOLOJİ
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectRHEUMATOLOGY
dc.subjectRomatoloji
dc.subjectRheumatology
dc.subjectadherence
dc.subjectmonotherapy
dc.subjectrheumatoid arthritis
dc.subjectsurvival
dc.subjecttofacitinib
dc.titleUnintentional monotherapy in rheumatoid arthritis patients receiving tofacitinib and drug survival rate of tofacitinib
dc.typearticle
dspace.entity.typePublication
local.avesis.idf0046e5b-e75c-4432-91f4-bec6725ec504
local.indexed.atPUBMED
local.indexed.atSCOPUS
local.indexed.atWOS
relation.isAuthorOfPublicationc963a17b-4775-4dd7-8db7-ea072cc49ef1
relation.isAuthorOfPublication.latestForDiscoveryc963a17b-4775-4dd7-8db7-ea072cc49ef1

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1.pdf
Size:
148.94 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs